<DOC>
	<DOCNO>NCT01786512</DOCNO>
	<brief_summary>The primary objective study ( ) select oral modify release ( MR ) formulation dose omecamtiv mecarbil chronic twice daily ( BID ) dose subject HF leave ventricular systolic dysfunction ( ii ) characterize pharmacokinetics ( PK ) 20 week treatment .</brief_summary>
	<brief_title>COSMIC-HF - Chronic Oral Study Myosin Activation Increase Contractility Heart Failure .</brief_title>
	<detailed_description>Omecamtiv mecarbil ( AMG 423 , CK-1827452 ) novel small molecule increase cardiac contractility selectively directly activate enzymatic domain cardiac myosin heavy chain , force-generating motor protein cardiac sarcomere . This randomized , placebo-controlled , multicenter , phase 2 study , consist dose escalation phase select 1 3 omecamtiv mecarbil oral formulation 2 dose escalation cohort , follow expansion phase evaluate 20 week administration select omecamtiv mecarbil formulation 2 target dose level , compare placebo .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Ventricular Dysfunction , Left</mesh_term>
	<criteria>History chronic HF , define require treatment HF minimum 4 week prior screen Treated stable , optimal pharmacological therapy ≥ 4 week History leave ventricular ejection fraction ( LVEF ) ≤ 40 % Elevated Nterminal fragment BNP ( NTproBNP ) Exclusion criterion : Severe uncorrected valvular heart disease Hospitalization within 30 day prior enrollment Hypertrophic obstructive cardiomyopathy , active myocarditis , constrictive pericarditis , clinically significant congenital heart disease Acute Myocardial Infarction , Unstable angina persistent angina rest within 30 day prior randomization Systolic BP &gt; 160 mmHg &lt; 90 mmHg diastolic BP &gt; 90 mmHg TBL ≥ 2x ULN ; AST ALT ≥ 3x ULN Estimated glomerular filtration rate ( eGFR ) &lt; 30 mL/min/1.73m2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Omecamtiv mecarbil</keyword>
	<keyword>AMG 423</keyword>
	<keyword>Double-blind</keyword>
	<keyword>Randomized</keyword>
	<keyword>Placebo-controlled</keyword>
	<keyword>Oral forumlation</keyword>
	<keyword>CK-1827452</keyword>
	<keyword>Cardiac myosin activator</keyword>
</DOC>